We have previously detailed our clinical results using a TLR-4-activated dendritic cell vaccine to engender an antigen-specific immune response and prevent recurrence of HER-2/neu-positive ductal carcinoma in situ [13]. The gene discussed is TLR4; the disease is ductal breast carcinoma in situ.